Skip to main content
Erschienen in: Journal of Bone and Mineral Metabolism 1/2019

20.02.2018 | Original Article

Decreased bone mineral density in women with Sheehan’s syndrome and improvement following oestrogen replacement and nutritional supplementation

verfasst von: Purnima Agarwal, Ramesh Gomez, Eesh Bhatia, Subhash Yadav

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Sheehan’s syndrome (SS) is an important cause of pan-hypopituitarism in women. There is scanty information on bone mineral density (BMD) in this condition. We determined BMD and the changes in BMD after oestrogen (E2) replacement and nutritional supplementation in women with SS. In a cross-sectional study, BMD was measured by DEXA in 83 patients [age (mean ± SD) 42 ± 9.2 years] and compared with an equal number of matched controls. In a sub-set of 19 patients, we conducted an open-label, prospective study to determine changes in BMD after 1 year of replacement of E2, and calcium and vitamin D3 supplementation. All patients had low serum IGF-1 and E2, while 98% had ≥ 3 pituitary hormone deficiencies. Compared with Indian reference standards, 47% had decreased bone mass (Z-score ≤ − 2.0). BMD Z-scores were decreased at all sites, being most marked in the lumbar spine and femoral neck. At the lumbar spine, BMD was lowest among the age group 21–30 years. Women with SS also had significantly lower BMD Z-scores at all three sites on comparison with ethnic controls. On multivariate analysis, BMD Z-score was associated with weight, daily calcium intake and age (lumbar spine). In the prospective study, 1 year of therapy improved BMD Z-score at lumbar spine (− 1.4 ± 1.2 vs. − 1.1 ± 1.1, p = 0.02), but not at hip or femoral neck. In conclusion, patients with SS had significantly lower BMD compared to controls at all three sites. Replacement of E2 and supplementation with calcium/vitamin D3 lead to significant improvement in lumbar spine BMD.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Karaca Z, Laway BA, Dokmetas HS, Atmaca H, Kelestimur F (2016) Sheehan syndrome. Nat Rev Dis Primers 2:16092CrossRefPubMed Karaca Z, Laway BA, Dokmetas HS, Atmaca H, Kelestimur F (2016) Sheehan syndrome. Nat Rev Dis Primers 2:16092CrossRefPubMed
2.
Zurück zum Zitat Diri H, Tanriverdi F, Karaca Z, Senol S, Unluhizarci K, Durak AC, Atmaca H, Kelestimur F (2014) Extensive investigation of 114 patients with Sheehan’s syndrome: a continuing disorder. Eur J Endocrinol 17:1311–1318 Diri H, Tanriverdi F, Karaca Z, Senol S, Unluhizarci K, Durak AC, Atmaca H, Kelestimur F (2014) Extensive investigation of 114 patients with Sheehan’s syndrome: a continuing disorder. Eur J Endocrinol 17:1311–1318
3.
Zurück zum Zitat Tessnow AH, Wilson JD (2010) The changing face of Sheehan’s syndrome. Am J Med Sci 340:402–406CrossRefPubMed Tessnow AH, Wilson JD (2010) The changing face of Sheehan’s syndrome. Am J Med Sci 340:402–406CrossRefPubMed
4.
Zurück zum Zitat Du GL, Liu ZH, Chen M, Ma R, Jiang S, Shayiti M, Zhu J, Yusufu A (2015) Sheehan’s syndrome in Xinjiang: clinical characteristics and laboratory evaluation of 97 patients. Hormones 14:660–667PubMed Du GL, Liu ZH, Chen M, Ma R, Jiang S, Shayiti M, Zhu J, Yusufu A (2015) Sheehan’s syndrome in Xinjiang: clinical characteristics and laboratory evaluation of 97 patients. Hormones 14:660–667PubMed
5.
Zurück zum Zitat Gei-Guardia O, Soto-Herrera E, Gei-Brealey A, Chen-Ku CH (2011) Sheehan syndrome in Costa Rica: clinical experience with 60 cases. Endocr Pract 17:337–344CrossRefPubMed Gei-Guardia O, Soto-Herrera E, Gei-Brealey A, Chen-Ku CH (2011) Sheehan syndrome in Costa Rica: clinical experience with 60 cases. Endocr Pract 17:337–344CrossRefPubMed
6.
Zurück zum Zitat Zargar AH, Singh B, Laway BA, Masoodi SR, Wani AI, Bashir MI (2005) Epidemiologic aspects of postpartum pituitary hypofunction (Sheehan’s syndrome). Fertil Sterl 84:523–528CrossRef Zargar AH, Singh B, Laway BA, Masoodi SR, Wani AI, Bashir MI (2005) Epidemiologic aspects of postpartum pituitary hypofunction (Sheehan’s syndrome). Fertil Sterl 84:523–528CrossRef
7.
Zurück zum Zitat Kristjansdottir HL, Bodvarsdottir SP, Sigurjonsdottir HA (2011) Sheehan’s syndrome in modern times: a nationwide retrospective study in Iceland. Eur J Endocrinol 164:349–354CrossRefPubMed Kristjansdottir HL, Bodvarsdottir SP, Sigurjonsdottir HA (2011) Sheehan’s syndrome in modern times: a nationwide retrospective study in Iceland. Eur J Endocrinol 164:349–354CrossRefPubMed
8.
Zurück zum Zitat Ramiandrasoa C, Castinetti F, Raingeard I, Fenichel P, Chabre O, Brue T, Courbière B (2013) Delayed diagnosis of Sheehan’s syndrome in a developed country: a retrospective cohort study. Eur J Endocrinol 169:431–438CrossRefPubMed Ramiandrasoa C, Castinetti F, Raingeard I, Fenichel P, Chabre O, Brue T, Courbière B (2013) Delayed diagnosis of Sheehan’s syndrome in a developed country: a retrospective cohort study. Eur J Endocrinol 169:431–438CrossRefPubMed
9.
Zurück zum Zitat Almeida M, Laurent MR, Dubois V, Claessens F, O’Brien CA, Bouillon R, Vanderschueren D, Manolagas SC (2017) Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev 97:135–187CrossRefPubMed Almeida M, Laurent MR, Dubois V, Claessens F, O’Brien CA, Bouillon R, Vanderschueren D, Manolagas SC (2017) Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev 97:135–187CrossRefPubMed
10.
Zurück zum Zitat Tritos NA, Klibanski A (2016) Effects of growth hormone on bone. Prog Mol Biol Transl Sci 138:193–211CrossRefPubMed Tritos NA, Klibanski A (2016) Effects of growth hormone on bone. Prog Mol Biol Transl Sci 138:193–211CrossRefPubMed
11.
Zurück zum Zitat Barake M, Klibanski A, Tritos NA (2014) Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab 99:852–860CrossRefPubMed Barake M, Klibanski A, Tritos NA (2014) Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab 99:852–860CrossRefPubMed
12.
Zurück zum Zitat Tritos NA, Greenspan SL, King D, Hamrahian A, Cook DM, Jönsson PJ, Wajnrajch MP, Koltowska-Häggstrom M, Biller BM (2011) Unreplaced sex steroid deficiency, corticotropin deficiency, and lower IGF-I are associated with lower bone mineral density in adults with growth hormone deficiency: a KIMS database analysis. J Clin Endocrinol Metab 96:1516–1523CrossRefPubMedPubMedCentral Tritos NA, Greenspan SL, King D, Hamrahian A, Cook DM, Jönsson PJ, Wajnrajch MP, Koltowska-Häggstrom M, Biller BM (2011) Unreplaced sex steroid deficiency, corticotropin deficiency, and lower IGF-I are associated with lower bone mineral density in adults with growth hormone deficiency: a KIMS database analysis. J Clin Endocrinol Metab 96:1516–1523CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Colao A, Di Somma C, Pivonello R, Loche S, Aimaretti G, Cerbone G, Faggiano A, Corneli G, Ghigo E, Lombardi G (1999) Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 84:1919–1924PubMed Colao A, Di Somma C, Pivonello R, Loche S, Aimaretti G, Cerbone G, Faggiano A, Corneli G, Ghigo E, Lombardi G (1999) Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 84:1919–1924PubMed
14.
Zurück zum Zitat Rosén T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA (1997) Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 137:240–245CrossRefPubMed Rosén T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA (1997) Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 137:240–245CrossRefPubMed
15.
Zurück zum Zitat Cartwright B, Robinson J, Seed PT, Fogelman I, Rymer J (2016) Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomized controlled trial of the effects on bone mineral density. J Clin Endocrinol Metab 101:3497–3505CrossRefPubMed Cartwright B, Robinson J, Seed PT, Fogelman I, Rymer J (2016) Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomized controlled trial of the effects on bone mineral density. J Clin Endocrinol Metab 101:3497–3505CrossRefPubMed
16.
Zurück zum Zitat Gotherstrom G, Bengtsson B-A, Bosæus I, Johannsson G, Svensson J (2007) Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J Endocrinol 156:55–56CrossRefPubMed Gotherstrom G, Bengtsson B-A, Bosæus I, Johannsson G, Svensson J (2007) Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J Endocrinol 156:55–56CrossRefPubMed
17.
Zurück zum Zitat Mo D, Fleseriu M, Qi R, Jia N, Child CJ, Bouillon R, Hardin DS (2015) Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol 3:331–338CrossRefPubMed Mo D, Fleseriu M, Qi R, Jia N, Child CJ, Bouillon R, Hardin DS (2015) Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol 3:331–338CrossRefPubMed
18.
Zurück zum Zitat Acibucu Fettah, Kilicli F, Sebila Dokmetas H (2014) Bone mineral density in Sheehan’s syndrome. Gynecol Endocrinol 30:532–535CrossRefPubMed Acibucu Fettah, Kilicli F, Sebila Dokmetas H (2014) Bone mineral density in Sheehan’s syndrome. Gynecol Endocrinol 30:532–535CrossRefPubMed
19.
Zurück zum Zitat Gokalp D, Tuzcu A, Bahceci M, Arikan S, Ozmen CA, Cil T (2009) Sheehan’s syndrome and its impact on bone mineral density. Gynecol Endocrinol 25:344–348CrossRefPubMed Gokalp D, Tuzcu A, Bahceci M, Arikan S, Ozmen CA, Cil T (2009) Sheehan’s syndrome and its impact on bone mineral density. Gynecol Endocrinol 25:344–348CrossRefPubMed
20.
Zurück zum Zitat Chihaoui M, Yazidi M, Chaker F, Belouidhnine M, Kanoun F, Lamine F, Ftouhi B, Sahli H, Slimane H (2016) Bone mineral density in Sheehan’s syndrome; prevalence of low bone mass and associated factors. J Clin Densitom 19:413–418CrossRefPubMed Chihaoui M, Yazidi M, Chaker F, Belouidhnine M, Kanoun F, Lamine F, Ftouhi B, Sahli H, Slimane H (2016) Bone mineral density in Sheehan’s syndrome; prevalence of low bone mass and associated factors. J Clin Densitom 19:413–418CrossRefPubMed
21.
Zurück zum Zitat Tanriverdi F, Unluhizarci K, Kula M, Guven M, Bayram F, Kelestimur F (2016) Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan’s syndrome. Growth Horm IGF Res 15:231–237CrossRef Tanriverdi F, Unluhizarci K, Kula M, Guven M, Bayram F, Kelestimur F (2016) Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan’s syndrome. Growth Horm IGF Res 15:231–237CrossRef
22.
Zurück zum Zitat Shatrugna V, Kulkarni B, Kumar PA, Rani KU, Balakrishna N (2005) Bone status of Indian women from a low-income group and its relationship to the nutritional status. Osteoporos Int 16:1827–1835CrossRefPubMed Shatrugna V, Kulkarni B, Kumar PA, Rani KU, Balakrishna N (2005) Bone status of Indian women from a low-income group and its relationship to the nutritional status. Osteoporos Int 16:1827–1835CrossRefPubMed
24.
Zurück zum Zitat Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930CrossRef Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930CrossRef
27.
Zurück zum Zitat Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148CrossRefPubMed Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148CrossRefPubMed
28.
Zurück zum Zitat Kelestimur F, Jonsson P, Molvalilar S, Gomez JM, Auernhammer CJ, Colak R, Koltowska-Häggström M, Goth MI (2005) Sheehan’s syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS–Pfizer International Metabolic Database. Eur J Endocrinol 152:581–587CrossRefPubMed Kelestimur F, Jonsson P, Molvalilar S, Gomez JM, Auernhammer CJ, Colak R, Koltowska-Häggström M, Goth MI (2005) Sheehan’s syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS–Pfizer International Metabolic Database. Eur J Endocrinol 152:581–587CrossRefPubMed
29.
Zurück zum Zitat De Laet C, Kanis JA, Odén A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P, McCloskey EV, Mellstrom D, Melton LJ 3rd, Meunier PJ, Pols HA, Reeve J, Silman A, Tenenhouse A (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330–1338CrossRefPubMed De Laet C, Kanis JA, Odén A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P, McCloskey EV, Mellstrom D, Melton LJ 3rd, Meunier PJ, Pols HA, Reeve J, Silman A, Tenenhouse A (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330–1338CrossRefPubMed
30.
Zurück zum Zitat Emaus N, Wilsgaard T, Ahmed LA (2005) Impacts of body mass index, physical activity, and smoking on femoral bone loss: the Tromsø study. J Bone Miner Res 29:2080–2089CrossRef Emaus N, Wilsgaard T, Ahmed LA (2005) Impacts of body mass index, physical activity, and smoking on femoral bone loss: the Tromsø study. J Bone Miner Res 29:2080–2089CrossRef
31.
Zurück zum Zitat Warensjö E, Byberg L, Melhus H, Gedeborg R, Mallmin H, Wolk A, Michaëlsson K (2011) Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. BMJ 342:d1473CrossRefPubMedPubMedCentral Warensjö E, Byberg L, Melhus H, Gedeborg R, Mallmin H, Wolk A, Michaëlsson K (2011) Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. BMJ 342:d1473CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Arya V, Bhambri R, Godbole MM, Mithal A (2004) Vitamin D status and its relationship with bone mineral density in healthy Asian Indians. Osteoporos Int 15:56–61CrossRefPubMed Arya V, Bhambri R, Godbole MM, Mithal A (2004) Vitamin D status and its relationship with bone mineral density in healthy Asian Indians. Osteoporos Int 15:56–61CrossRefPubMed
33.
Zurück zum Zitat Popat VB, Calis KA, Vanderhoof VH, Cizza G, Reynolds JC, Sebring N, Troendle JF, Nelson LM (2009) Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab 94:2277–2283CrossRefPubMedPubMedCentral Popat VB, Calis KA, Vanderhoof VH, Cizza G, Reynolds JC, Sebring N, Troendle JF, Nelson LM (2009) Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab 94:2277–2283CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Isotton AL, Wender MC, Casagrande A, Rollin G, Czepielewski MA (2012) Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study. Eur J Endocrinol 166:207–213CrossRefPubMed Isotton AL, Wender MC, Casagrande A, Rollin G, Czepielewski MA (2012) Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study. Eur J Endocrinol 166:207–213CrossRefPubMed
36.
Zurück zum Zitat Foo J-P, Hamnvik O-P, Mantzoros CS (2012) Optimizing bone health in anorexia nervosa and hypothalamic amenorrhea: new trials and tribulations. Metabolism 61:899–905CrossRefPubMedPubMedCentral Foo J-P, Hamnvik O-P, Mantzoros CS (2012) Optimizing bone health in anorexia nervosa and hypothalamic amenorrhea: new trials and tribulations. Metabolism 61:899–905CrossRefPubMedPubMedCentral
Metadaten
Titel
Decreased bone mineral density in women with Sheehan’s syndrome and improvement following oestrogen replacement and nutritional supplementation
verfasst von
Purnima Agarwal
Ramesh Gomez
Eesh Bhatia
Subhash Yadav
Publikationsdatum
20.02.2018
Verlag
Springer Japan
Erschienen in
Journal of Bone and Mineral Metabolism / Ausgabe 1/2019
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-018-0911-6

Weitere Artikel der Ausgabe 1/2019

Journal of Bone and Mineral Metabolism 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.